MiR-93 enhances angiogenesis and metastasis by targeting LATS2

…, ZJ Rutnam, C Peng, H Li, YQ O'Malley, RW Askeland… - Cell cycle, 2012 - Taylor & Francis
Here we report that miR-93, a miRNA in the miR-106B~25 cluster, a paralog of the miR-17–92
cluster, was significantly upregulated in human breast carcinoma tissues. We stably …

MicroRNA miR-24 enhances tumor invasion and metastasis by targeting PTPN9 and PTPRF to promote EGF signaling

…, W Qian, YQ O'Malley, RW Askeland… - Journal of cell …, 2013 - journals.biologists.com
MicroRNAs are known to play regulatory roles in gene expression associated with cancer
development. We analyzed levels of the microRNA miR-24 in patients with breast carcinoma …

Paracrine WNT5A signaling inhibits expansion of tumor-initiating cells

…, R Kolb, Q Xie, W Li, F Yuan, G Velez, R Askeland… - Cancer research, 2015 - AACR
Ryan Askeland who is a clinical pathologist and defined the intensity of WNT5A staining.
The staining intensity of WNT5A was given a scoring system as 0, 1+, 2+, and 3+. For example, …

[HTML][HTML] Regulator of G protein signaling 6 (RGS6) induces apoptosis via a mitochondrial-dependent pathway not involving its GTPase-activating protein activity

B Maity, J Yang, J Huang, RW Askeland, S Bera… - Journal of biological …, 2011 - ASBMB
Regulator of G protein signaling 6 (RGS6) is a member of a family of proteins called RGS
proteins, which function as GTPase-activating proteins (GAPs) for Gα subunits. Given the role …

Regulator of G protein signaling 6 is a novel suppressor of breast tumor initiation and progression

B Maity, A Stewart, Y O'Malley, RW Askeland… - …, 2013 - academic.oup.com
Breast cancer is a large global health burden and the most frequently diagnosed malignancy
in women worldwide. Here, we utilize RGS6 − /− mice to interrogate the role of regulator of …

Inhibition of RET increases the efficacy of antiestrogen and is a novel treatment strategy for luminal breast cancer

PM Spanheimer, JM Park, RW Askeland, MV Kulak… - Clinical cancer …, 2014 - AACR
Purpose: Recent findings suggest that combination treatment with antiestrogen and anti-RET
may offer a novel treatment strategy in a subset of patients with breast cancer. We …

RABL6A Promotes G1–S Phase Progression and Pancreatic Neuroendocrine Tumor Cell Proliferation in an Rb1-Dependent Manner

…, FA Gourronc, AJ Klingelhutz, HJ Major, RW Askeland… - Cancer research, 2014 - AACR
Mechanisms of neuroendocrine tumor (NET) proliferation are poorly understood, and
therapies that effectively control NET progression and metastatic disease are limited. We found …

[HTML][HTML] RGS6 is an essential tumor suppressor that prevents bladder carcinogenesis by promoting p53 activation and DNMT1 downregulation

…, Z Lin, B Chakravarti, SR Ibeawuchi, RW Askeland… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Urinary bladder cancer (UBC) is largely caused by exposure to toxic chemicals including those
in cigarette smoke (ie BBN). An activating SNP in RGS6 is associated with a pronounced …

RABL6A promotes oxaliplatin resistance in tumor cells and is a new marker of survival for resected pancreatic ductal adenocarcinoma patients

VP Muniz, RW Askeland, X Zhang, SM Reed… - Genes & …, 2013 - journals.sagepub.com
Pancreatic ductal adenocarcinoma (PDAC) is characterized by early recurrence following
pancreatectomy, rapid progression, and chemoresistance. Novel prognostic and predictive …

Enhancing transfusion safety with an innovative bar-code-based tracking system.

RW Askeland, SP McGrane, DR Reifert… - … Quarterly (Toronto, Ont …, 2009 - europepmc.org
In an effort to reduce transfusion errors, a novel, comprehensive, computerized wireless bar-code-based
tracking system for matching patients, blood samples and blood products was …